Protection against postoperative atrial fibrillation via antiplatelet aggregation induced by remote ischemic preconditioning during off-pump coronary artery bypass grafting.

Basic Res CardiolJul 3, 2026 (epub)
Clinical ResearchCardiologyCardiothoracic SurgeryOpen access

Qin Jiang, Yi Zheng, Keli Huang et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of remote ischemic preconditioning (RIPC) on postoperative atrial fibrillation (POAF) in patients with CYP2C19 loss-of-function genotype undergoing off-pump coronary artery bypass grafting (OPCABG). Among 220 patients, POAF occurred in 24.8% of the RIPC group compared to 41.4% in the control group (HR: 0.542, P = 0.01), indicating a significant reduction in incidence.

Key findings

  • POAF incidence was 24.8% in the RIPC group versus 41.4% in the control group (HR: 0.542, P = 0.01).
  • The RIPC group had a significantly lower AF burden of 5.1% compared to 8.3% in the control group (P = 0.019).
  • RIPC reduced platelet aggregation and systemic inflammation compared to the control group.
  • Patients in the RIPC group had a shorter intensive care unit stay.

Why it matters

The findings suggest that RIPC may be an effective strategy to reduce the incidence of POAF and associated complications in high-risk patients undergoing OPCABG, potentially improving postoperative outcomes.

Source

PubMed · PMID 42397565Free full text on PubMed Central

Published in Basic Res Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.